All eligible patients will receive induction chemotherapy prior to consideration of primary surgical intervention. If surgical intervention is deemed not to be in the best interest of the patient, patient will go off study at the time of evaluation for surgery. Upon completion of chemotherapy and surgery, all ER + and/or PR + patients will be placed on Tamoxifen 20 mg/qd or an aromatase inhibitor.
Induction preoperative therapy:
* Bevacizumab
* Trastuzumab
* ABI-007
* Carboplatin
Postoperative Adjuvant Therapy:
* Bevacizumab
* Trastuzumab
